Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, phase i trial with an extensive biomarker program

Markus Moehler*, Annett Maderer, Anne Ehrlich, Friedrich Foerster, Arno Schad, Tanja Nickolay, Christian Ruckes, Arndt Weinmann, Visvakanth Sivanathan, Jens U. Marquardt, Peter Robert Galle, Marcus Woerns, Thomas Thomaidis

*Korrespondierende/r Autor/-in für diese Arbeit
15 Zitate (Scopus)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, phase i trial with an extensive biomarker program“. Zusammen bilden sie einen einzigartigen Fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science